Enzene Biosciences launches Ranibizumab to treat neovascular AMD EP News Bureau Nov 24, 2023 Ranibizumab biosimilar is the company’s seventh biosimilar
Investment in novel therapies key priority to tackle AMR: GlobalData EP News Bureau Nov 24, 2023 As per GlobalData Pharmaceutical Intelligence Center’s pipeline drugs database, there are around 929 antibiotics and 182…
Sanjivani Paranteral, Hindustan Antibiotics partner to manufacture IV formulations and IV Sets EP News Bureau Nov 24, 2023 The partnership will see the establishment of a manufacturing facility within the premises of Hindustan Antibiotics at Pimpri…
Experts believe gene therapies will disrupt Gaucher disease drug market: GlobalData EP News Bureau Nov 23, 2023 Gaucher disease, a rare inherited metabolic disorder caused by defects in the GBA1 gene, results in harmful glucocerebroside…
Strides gets USFDA approval for generic Suprep Bowel Prep Kit EP News Bureau Nov 23, 2023 The product belongs to a group of medicines prescribed to those who are required to undergo a colon cleanse prior to a colonoscopy
Lupin launches FDC drug Vilfuro-G for COPD management in India EP News Bureau Nov 23, 2023 The launch follows the approval granted by the Drug Controller General of India for the dry powder inhaler (DPI) product
Evive, Acrotech get FDA nod for Ryzneuta (Efbemalenograstim alfa Injection) for chemo-induced… EP News Bureau Nov 22, 2023 Neutropenia is characterised by persistently low levels of neutrophils due to the use of chemotherapy and other types of…
Lupin gets US FDA approval for Dapagliflozin tablets and Pitavastatin tablets EP News Bureau Nov 21, 2023 Both the products will be manufactured at Lupin’s Pithampur facility in India
Strides gets USFDA approval for Levetiracetam Oral Solution EP News Bureau Nov 21, 2023 It is used in the treatment of seizures
Sugemalimab approval in China makes it only second drug approved globally for ENKTL: GlobalData EP News Bureau Nov 20, 2023 GlobalData forecasts sugemalimab to generate sales of $31 million (patient-based forecast) by 2030 for T-cell lymphomas in China